Bumpus, director of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine. Antiviral pills, she says, “are not replacements, but they’re an important part of the tool kit.” Efforts to make such medicines are finally bearing fruit. In October, Merck & Co. and Ridgeback Biotherapeutics reported promising results for molnupiravir, which, like remdesivir, targets SARS-CoV-2’s RNA-dependent RNA polymerase—an enzyme that the virus needs to make copies of itself.
by Bethany Halford |
December 05, 2021